Aptevo Therapeutics Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Aptevo Therapeutics Inc. (APVO) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $58.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-14
- Aptevo Therapeutics Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $58.00K.
- Aptevo Therapeutics Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $57.00K, a 68.33% decline year-over-year.
- Aptevo Therapeutics Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $77.00K, a 48.32% decline year-over-year.
- Aptevo Therapeutics Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was -$163.00K, a 159.71% decline year-over-year.
- Aptevo Therapeutics Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $96.00K, a 91.02% decline from fiscal 2024.
- Aptevo Therapeutics Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $1.07M, a 51.25% decline from fiscal 2023.
- Aptevo Therapeutics Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $2.19M, a 21.70% increase from fiscal 2022.
- Aptevo Therapeutics Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $1.80M, a 9.68% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $58.00K 10-Q · filed 2026-08-14 | $115.00K derived: sum of 2 quarters · filed 2026-08-14 | ||
| 2026-03-31 | $57.00K 10-Q · filed 2026-08-14 | |||
| 2025-12-31 | $96.00K 10-K · filed 2026-03-26 | |||
| 2025-09-30 | $77.00K 10-Q · filed 2025-11-06 | -$86.00K derived: sum of 2 quarters · filed 2026-08-14 | $94.00K derived: sum of 3 quarters · filed 2026-08-14 | |
| 2025-06-30 | -$163.00K 10-Q · filed 2026-08-14 | $17.00K derived: sum of 2 quarters · filed 2026-08-14 | ||
| 2025-03-31 | $180.00K 10-Q · filed 2026-08-14 | |||
| 2024-12-31 | $1.07M 10-K · filed 2026-03-26 | |||
| 2024-09-30 | $149.00K 10-Q · filed 2025-11-06 | $422.00K derived: sum of 2 quarters · filed 2025-11-06 | $1.14M derived: sum of 3 quarters · filed 2025-11-06 | |
| 2024-06-30 | $273.00K 10-Q · filed 2025-11-06 | $992.00K derived: sum of 2 quarters · filed 2025-11-06 | ||
| 2024-03-31 | $719.00K 10-Q · filed 2025-11-06 | |||
| 2023-12-31 | $2.19M 10-K · filed 2025-02-14 | |||
| 2023-09-30 | $455.00K 10-Q · filed 2024-11-07 | $920.00K derived: sum of 2 quarters · filed 2024-11-07 | $1.83M derived: sum of 3 quarters · filed 2024-11-07 | |
| 2023-06-30 | $465.00K 10-Q · filed 2024-11-07 | $1.38M derived: sum of 2 quarters · filed 2024-11-07 | ||
| 2023-03-31 | $915.00K 10-Q · filed 2024-11-07 | |||
| 2022-12-31 | $1.80M 10-K · filed 2024-03-05 | |||
| 2022-09-30 | $359.00K 10-Q · filed 2023-11-14 | $844.00K derived: sum of 2 quarters · filed 2023-11-14 | $1.45M derived: sum of 3 quarters · filed 2023-11-14 | |
| 2022-06-30 | $485.00K 10-Q · filed 2023-11-14 | $1.09M derived: sum of 2 quarters · filed 2023-11-14 | ||
| 2022-03-31 | $601.00K 10-Q · filed 2023-11-14 | |||
| 2021-12-31 | $1.64M 10-K · filed 2023-03-30 | |||
| 2021-09-30 | $319.00K 10-Q · filed 2022-11-10 | $891.00K derived: sum of 2 quarters · filed 2022-11-10 | $1.47M derived: sum of 3 quarters · filed 2022-11-10 | $1.66M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $572.00K 10-Q · filed 2022-11-10 | $1.15M derived: sum of 2 quarters · filed 2022-11-10 | $1.34M derived: sum of 3 quarters · filed 2022-11-10 | $1.69M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-03-31 | $574.00K 10-Q · filed 2022-11-10 | $772.00K derived: sum of 2 quarters · filed 2022-11-10 | $1.11M derived: sum of 3 quarters · filed 2022-11-10 | $1.42M derived: sum of 4 quarters · filed 2022-11-10 |
| 2020-12-31 | $198.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-24 | $541.00K derived: sum of 2 quarters · filed 2022-03-24 | $842.00K derived: sum of 3 quarters · filed 2022-03-24 | $1.25M 10-K · filed 2022-03-24 |
| 2020-09-30 | $343.00K 10-Q · filed 2021-11-12 | $644.00K derived: sum of 2 quarters · filed 2021-11-12 | $1.06M 10-Q · filed 2020-11-10 | $1.33M derived: sum of 4 quarters · filed 2021-11-12 |
| 2020-06-30 | $301.00K 10-Q · filed 2021-11-12 | $714.00K 10-Q · filed 2020-08-14 | $983.00K derived: sum of 3 quarters · filed 2021-11-12 | $1.32M derived: sum of 4 quarters · filed 2021-11-12 |
| 2020-03-31 | $413.00K 10-Q · filed 2021-11-12 | $682.00K derived: sum of 2 quarters · filed 2021-11-12 | $1.02M derived: sum of 3 quarters · filed 2021-11-12 | $1.42M derived: sum of 4 quarters · filed 2021-11-12 |
| 2019-12-31 | $269.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-31 | $603.00K derived: sum of 2 quarters · filed 2021-03-31 | $1.00M derived: sum of 3 quarters · filed 2021-03-31 | $1.60M 10-K · filed 2021-03-31 |
| 2019-09-30 | $334.00K 10-Q · filed 2020-11-10 | $735.00K derived: sum of 2 quarters · filed 2020-11-10 | $1.33M 10-Q · filed 2020-11-10 | $1.82M derived: sum of 4 quarters · filed 2020-11-10 |
| 2019-06-30 | $401.00K 10-Q · filed 2020-08-14 | $995.00K 10-Q · filed 2020-08-14 | $1.49M derived: sum of 3 quarters · filed 2020-08-14 | $1.97M derived: sum of 4 quarters · filed 2020-08-14 |
| 2019-03-31 | $594.00K 10-Q · filed 2020-05-13 | $1.09M derived: sum of 2 quarters · filed 2020-05-13 | $1.57M derived: sum of 3 quarters · filed 2020-05-13 | $2.02M derived: sum of 4 quarters · filed 2020-05-13 |
| 2018-12-31 | $493.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-25 | $974.00K derived: sum of 2 quarters · filed 2020-03-25 | $1.42M derived: sum of 3 quarters · filed 2020-03-25 | $2.14M 10-K · filed 2020-03-25 |
| 2018-09-30 | $481.00K 10-Q · filed 2019-11-07 | $930.00K derived: sum of 2 quarters · filed 2019-11-07 | $1.65M 10-Q · filed 2019-11-07 | |
| 2018-06-30 | $449.00K 10-Q · filed 2019-08-09 | $1.17M 10-Q · filed 2019-08-09 | ||
| 2018-03-31 | $717.00K 10-Q · filed 2019-05-09 | |||
| 2017-12-31 | $4.88M 10-K · filed 2019-03-18 | |||
| 2016-12-31 | $1.74M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-13 | $3.81M 10-K · filed 2018-03-13 | ||
| 2016-09-30 | $2.07M 10-Q · filed 2016-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Onconetix, Inc. (ONCO) | United States | $0.004B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B |